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Abstract
Background Diabetes mellitus (DM) is an important risk
factor for stroke. Acetylsalicylic acid (ASA) is the most
frequently used medication for prevention of cardio-cere-
bral vascular diseases. However, some patients experience
ischaemic vascular events despite the use of ASA. This
phenomenon is known as ‘‘aspirin resistance’’ (AR). The
aim of this study was to assess the prevalence of AR in
diabetic patients and search for factors associated with it.
Materials and methods The examined group consisted of
96 subjects with diagnosed type 2 DM. Platelet function
test was performed by the method of whole blood imped-
ance aggregometry.
Results Among examined subjects, 51 patients (53.1 %)
were sensitive to ASA action (ASA responders) and 45
patients (46.9 %) were resistant to ASA action (ASA non-
responders). No association was found between platelet
aggregation and gender, age, dose of ASA, known duration
of diabetes, BMI, heart rate, mean systolic and diastolic
blood pressure, and risk factors except for current smoking
(p = 0.030). ASA non-responders were treated shorter
with ASA than ASA responders (p = 0.010). The mean
total cholesterol (p = 0.020), LDL concentration
(p = 0.005), HCT (p = 0.010), WBC (p = 0.030), and
PLT (p = 0.050) were significantly higher in ASA non-
responders. No association was found between AR and
results of other laboratory tests and medications. Multiple
logistic regression analysis revealed factors associated with
AR: current smoking and LDL concentration higher than
3.5 mmol/l.
Conclusions Results of our study did not confirm the
association between poor glycaemic control in the diabetic
patients and AR. Resistance to ASA in diabetic patients is
associated with lipid disorders and history of current
smoking.
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Introduction
Diabetes mellitus (DM) is an important and common
risk factor for stroke. People with DM suffer from
cerebrovascular events 1.5–3 times more likely than
people without disorders of carbohydrate metabolism.
Acetylsalicylic acid (ASA) is the most frequently used
medication for prevention of ischaemic events in dia-
betic patients. Recommendations for the cardiovascular
prevention and usage of ASA in diabetic patients are
nowadays similar to the general principles as for people
without diabetes. Recent randomized clinical trials and
meta-analyses did not confirm the effectiveness of ASA
in primary prevention in diabetic patients without other
risk factors [1–4]. Following the current European
guidelines [5], ASA is recommended in all patients with
an overt vascular disease (previous stroke, previous non-
cardioembolic cerebral transient ischaemic attack, cor-
onary heart disease, previous myocardial infarction,
peripheral artery disease). In asymptomatic people, also
in diabetic patients, ASA could be considered when the
risk of death from a cardiovascular disease is high (5 %
or greater in the next 10 years). On the basis of the risk
factors (gender, age, systolic blood pressure, total cho-
lesterol and history of smoking), one can determine the
risk of death from cardiovascular causes in patients aged
40 and older using tables of Systematic Coronary Risk
Evaluation (SCORE) [5, 6].
In patients who regularly take ASA a 25 % reduction
of the incidence of myocardial infarction and ischaemic
stroke was reported [7]. However, some patients do not
experience the positive antiplatelet effect and have
cardiovascular events despite the use of ASA. This
phenomenon is known as ‘‘clinical aspirin resistance’’
(AR). This term is also used when laboratory test
results indicate the lack of antiaggregative ASA action
(known as ‘‘biochemical aspirin resistance’’).The prev-
alence of AR described in the literature is up to 60 %
among subjects taking ASA for primary or secondary
prevention of cardiovascular episodes [8–15]. Some
authors noticed that AR occurred more frequently in
diabetic patients [16, 17]. The mechanism of AR has
not been fully understood as yet. Genetic factors are
considered together with patient non-compliance, low
dose of the drug, interactions with other medications
and substances [18]. In diabetic patients the role of
glycaemic control was also studied but the data con-
cerning association between poor control and AR are
conflicting [16, 17, 19–21].
The aim of this study was to assess the prevalence of AR
in diabetic patients and search for factors associated with
this phenomenon.
Materials and methods
Subjects for the study were recruited in 2011–2012 years
from patients treated in the Voivodship Outpatient Clinic
for Diabetic Patients in Zabrze, Poland. The recruitment for
the study was performed once a month. All the patients
attending the outpatient clinic on the recruitment day were
checked according to the inclusion and exclusion criteria.
Only those who agreed to take part in the study and gave
written consent were selected.
The inclusion criteria for the examined group were the
following: diagnosed diabetes mellitus type 2, known
cardiovascular disease (coronary heart disease, previous
myocardial infarct, previous stroke or transient ischaemic
attack, peripheral artery disease) or SCORE [ 5 %, regular
daily ASA intake at the dose of 75–150 mg/day, not using
other antiplatelet and/or anticoagulant agents, age between
18 and 80 years, and the patient’s informed written consent
for the study.
Diabetes mellitus was diagnosed according to the cur-
rent criteria of Polish Diabetological Society (clinical
symptoms of hyperglycaemia and casual glycemia C200
mg/dl or twice measured fasting glycemia C126 mg/dl or
glycemia in 120 min of OGTT C 200 mg/dl).
The 10-year risk of fatal cardiovascular disease
(SCORE) was assessed using the following data: sex (male/
female), age (years), systolic blood pressure (mmHg), total
cholesterol (mmol/l) and history of current smoking [5, 6].
The exclusion criteria for the examined group were the
following: the intake of other oral antiplatelet or antico-
agulant agents, the use of other non-steroidal anti-inflam-
matory drugs (NSAIDs), irregular ASA intake, the use of
heparin or low molecular weight heparin, platelet count
\100 9 103/ll or[450 9 103/ll, history of haemorrhage.
Patients with history of atrial fibrillation participating in
this study had contradictions for usage of oral anticoagu-
lant agents or did not agree for such treatment.
The regularity of ASA intake (one tablet per day) was
determined based on the carefully obtained medical his-
tory. Besides, the intake of ASA was personally controlled
by one of the authors on the day (24 h) before the study.
The study was approved by the Bioethics Committee of
the Medical University of Silesia.
All patients were interviewed and underwent physical
examination. Arterial hypertension was recognized in people
treated with antihypertensive drugs and in those who pre-
sented abnormal BP in two measurements (SBP C 140
mmHg and/or DBP C 90 mmHg). Dyslipidaemia was rec-
ognized in people treated with statins or fibrates and in those
who revealed abnormal results of lipids (total choles-
terol C 4.5 mmol/l and/or LDL C 2.6 mmol/l and/or TG C
1.7 mmol/l). Coronary heart disease, previous myocardial
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infarct and atrial fibrillation were recognized only when they
were documented.
A 10-ml fasting blood sample was obtained to determine
platelet function and additional laboratory tests (CBC,
glucose, total cholesterol, LDL, HDL, triglycerides,
HbA1C, CRP, creatinine). CBC was assessed by haema-
tological analyzer Sysmex K-4500 (Sysmex Polska), and
glucose, total cholesterol, HDL, triglycerides, HbA1C,
CRP, creatinine—by biochemical analyzer Cobas Integra
800 (Roche). Concentration of serum LDL cholesterol
was counted according to Friedwald schedule. The fol-
lowing methods were used: enzymatic colorimetric method
(total cholesterol, triglycerides, HDL), Jaffe’s method
(creatinine), immune turbidmetric method (CRP, HbA1C),
reference enzymatic method (glucose).
Platelet function test was performed by the method of
whole blood impedance aggregometry using multiple
platelet function analyzer Multiplate (Dynabyte Medical,
Munich, Germany) [22, 23]. Aggregation was triggered by
use of arachidonic acid (ASPItest). The results were
expressed as the area under curve (AUC) (Figs. 1, 2).
Based on the manufacturer’s data, it was accepted that in
patients who take ASA the value of AUC \ 300 indicates
aspirin sensitivity (ASA responders), and the value of
AUC C 300 indicates aspirin resistance (ASA non-
responders) [22–24].
The obtained results underwent statistical analysis using
STATISTICA 9.0, Stat Soft Poland. The result was
considered statistically significant if obtained significance
level was p B 0.05. In data description the standard statistical
parameters were provided, i.e. the number N, arithmetic mean
X, the standard deviation (SD) and percentages (%). Normal
distribution of data was assessed by Shapiro–Wilk normality
test. Statistical significance of between-group differences was
verified by U Mann–Whitney test. Chi-squared test was uti-
lized for comparison of qualified variables. Multiple logistic
regression analysis was performed for searching factors asso-
ciated with AR. Odds ratio (OR) and confidential interval (CI)
were calculated for the following factors: age [ 60 years,
male sex, dose of ASA B 100 mg per day, duration of ASA
therapy [ 1 year, known duration of diabetes[ 5 years,
BMI [ 25 kg/m2, systolic blood pressure C 140 mmHg,
diastolic blood pressure C 90 mmHg, heart rate C 80 bpm,
presence of each cardiovascular risk factor, each medication,
RBC \ 4 9 106/ll, RBC [ 4 9 106/ll, HGB \ 11 g/dl,
HGB [ 14 g/dl, HCT \ 35 %, HCT [ 40 %, WBC [ 10 9
103/ll, PLT [ 300 9 103/ll, HbA1C [ 6 %, total choles-
terol[5.2 mmol/l, LDL[3.5 mmol/l, HDL\1.55 mmol/l,
TG [ 1.7 mmol/l, CRP [ 5 mg/dl, glukoza [ 110 mg/dl,
kreatynina [ 1.3 mg/l.
Results
The examined group consisted of 96 subjects (48 female
and 48 male) with diagnosed diabetes mellitus type 2
Fig. 1 An example of platelet
function analysis (ASPI test)
with usage of multiple platelet
function analyzer. Resistance to
ASA was recognized in
examined patient
Fig. 2 An example of platelet
function analysis (ASPI test)
with usage of multiple platelet
function analyzer. Proper
response to ASA was
recognized in examined patient
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(mean age 65.3 ± 8.1, mean known duration of DM
9.9 ± 8.1). 53 patients (55.2 %) were treated with oral
hypoglycaemic drugs, 41 (42.7 %)—with insulin, and 2
(2.1 %) were only on the hypoglycaemic diet.
Among them, 51 patients (53.1 %) were sensitive to
ASA action (ASA responders) and 45 patients (46.9 %)
were resistant to ASA action (ASA non-responders).
Clinical characteristics of the examined patients and the
ASA response groups are shown in Table 1. The occur-
rence of other cardiovascular risk factors, the intake of
medications and the results of laboratory tests are shown in
Tables 2, 3, and 4.
No association was found between platelet aggregation
and the gender, age, the dose of ASA, known duration of
diabetes, BMI, heart rate, mean systolic and diastolic blood
pressure. Patients resistant to ASA were treated shorter
with ASA than ASA responders (p = 0.010). No
association was found between the occurrence of ASA
resistance and the risk factors found in patients except for
current smoking (Table 2).
The mean total cholesterol (p = 0.020), LDL concen-
tration (p = 0.005), HCT (p = 0.010), WBC (p = 0.030),
and PLT (p = 0.050) were significantly higher in ASA
non-responders compared to ASA responders. No associ-
ation was found between the aggregation parameters and
the results of the other laboratory tests (Table 3).
No statistically significant association was found
between the intake of different medications and the
occurrence of ASA resistance (Table 4).
Multiple logistic regression analysis revealed the
factors associated with AR: history of current smoking
(OR 3.79, CI 1.08–13.3, p = 0.040), and LDL concentra-
tion higher than 3.5 mmol/l (OR 5.58, CI 1.26–24.8,
p = 0.020).
Table 1 Clinical characteristics of all the examined patients and ASA response groups
All the patients (N = 96) ASA responders (N = 51) ASA non-responders (N = 45) p value
Female/malea 48 (50 %)/48 (50 %) 25 (49 %)/26 (51 %) 23 (51 %)/22 (49 %) NS#
Age (years)b 65.3 ± 8.1 66.7 ± 7 63.9 ± 7.9 NS##
ASA (75 mg)/ASA (150 mg)a 55 (57 %)/41 (43 %) 29 (57 %)/22 (43 %) 26 (58 %)/19 (42 %) NS#
Duration of ASA therapy (years)b 4.9 ? 3.6 5.7 ± 3.9 3.9 ± 2.9 0.010##
Known duration of diabetes (years)b 9.9 ± 8.1 10.8 ± 8.1 8.6 ± 7.9 NS##
BMI (kg/m2)b 30.1 ± 4.6 30.2 ± 4.9 30.1 ± 4.4 NS##
HR (bpm)b 74.9 ± 7.8 74.1 ± 7.5 75.7 ± 8.0 NS##
SBP (mmHg)b 134.4 ± 13.7 134.6 ± 12.5 134.1 ± 14.9 NS##
DBP (mmHg)b 78.8 ± 7.9 77.6 ± 8.3 80.0 ± 7.5 NS##
BMI body mass index, ASA acetylsalicylic acid, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure
# v2 test
## U Mann–Whitney test
a Data presented as N (%)
b Data presented as mean ± SD
Table 2 Cardiovascular risk factors present in all the examined patients and ASA response groups
Risk factor All the patients (N = 96) ASA responders (N = 51) ASA non-responders (N = 45) p value*
Arterial hypertension 90 (93.8 %) 48 (94.1 %) 42 (93.3 %) NS
Coronary heart disease 50 (52.1 %) 28 (54.9 %) 22 (48.9 %) NS
Previous myocardial infarct 19 (19.8 %) 10 (19.6 %) 9 (20 %) NS
Previous stroke 30 (31.3 %) 16 (53.3 %) 14 (46.7 %) NS
Dyslipidaemia 85 (88.5 %) 44 (86.3 %) 41 (91.1 %) NS
Atrial fibrilation 23 (23.9 %) 12 (23.5 %) 11 (24.4 %) NS
Current smoking 15 (15.6 %) 4 (7.8 %) 11 (24.4 %) 0.030
Overweight or obesity** 83 (86.5 %) 44 (86.3 %) 39 (86.7 %) NS
In brackets frequencies of occurrence of risk factors in each group are shown, N (%)
* v2 test
** BMI [ 25 kg/m2
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Discussion
The results of some experimental studies show the signif-
icant influence of hyperglycaemia on platelet function
since it results in increased prothrombotic condition and
proinflammatory functions promoting atherosclerosis and
acute vascular episodes by the induction of platelet acti-
vation and expression of tissue factor in monocytes. Hy-
perglycaemia can also be related to the decreased
sensitivity to ASA [9, 25, 26]. In our study we did not
observe the influence of poor glycaemic control on inci-
dence of AR in diabetic patients. We neither noticed
association between fasting blood glucose nor HBA1C
level and platelet function. In the literature the results
concerning the phenomenon of AR and glycaemic control
in the diabetic patients are conflicting. Some authors,
similar to our results, did not observe association between
AR and parameters of glycaemic control [20, 21]. On the
other hand, Ertugrul et al. investigated 108 diabetic patients
and found that AR correlated positively with fasting blood
glucose and HbA1C. In this study the patients with poor
glycaemic control (HbA1C [ 7 %) had significantly
higher AR [16]. Association of AR with HbA1C was also
observed by Cohen et al. [19] and Watala et al. [17].
We noticed association between AR and lipid disorders
in diabetic patients. ASA non-responders had significantly
Table 3 Laboratory results (mean ± SD) in all the examined patients and ASA response groups
Laboratory results All the patients (N = 96) ASA responders (N = 51) ASA non-responders (N = 45) p value*
RBC (106/ll) 4.7 ± 1.3 4.5 ± 0.5 4.9 ± 1.9 NS
HCT (%) 40.2 ± 5.4 38.8 ± 6.2 41.6 ± 3.9 0.010
HGB (g/dl) 13.6 ± 1.5 13.3 ± 1.4 13.9 ± 1.6 NS
WBC (103/ll) 7.1 ± 2.2 6.6 ± 1.9 7.7 ± 2.5 0.030
PLT (103/ll) 240.5 ± 66.6 225.1 ± 61.6 257.3 ± 68.4 0.050
Total cholesterol (mmol/l) 4.8 ± 1.3 4.6 ± 1.2 5.2 ± 1.3 0.020
LDL (mmol/l) 3.1 ± 1.2 2.9 ± 1.1 3.5 ± 1.2 0.005
HDL (mmol/l) 1.3 ± 0.4 1.4 ± 0.4 1.3 ± 0.4 NS
TG (mmol/l) 1.6 ± 1.4 1.5 ± 0.7 1.7 ± 0.9 NS
Fasting glucose (mg/dl) 140 ± 60 142.1 ± 70.5 139.1 ± 46.7 NS
HbA1C (%) 7.7 ± 6.2 7.9 ± 8.4 7.3 ± 1.7 NS
CRP (mg/l) 3.2 ± 5.7 3.3 ± 5.2 3.1 ± 6.3 NS
Creatinine (mg/l) 0.87 ± 0.2 0.8 ± 0.2 0.9 ± 0.3 NS
RBC red blood cells, HCT haematocrit, HGB haemoglobin, WBC white blood cells, PLT platelets, LDL low density lipoproteins, HDL high
density lipoproteins, TG triglycerides, CRP C-reactive protein, HbA1C glycated haemoglobin A1C
* U Mann–Whitney test
Table 4 Additional medications used in all the examined patients and ASA response groups
Medication All the patients (N = 96) ASA responders (N = 51) ASA non-responders (N = 45) p value*
Oral hypoglycaemics 53 (55.2 %) 28 (54.9 %) 25 (55.6 %) NS
Insulin 41 (42.7 %) 22 (43.1 %) 19 (42.2 %) NS
Diuretics 29 (30.2 %) 19 (37.3 %) 10 (22.2 %) NS
ACE inhibitors 73 (76.0 %) 36 (70.6 %) 37 (87.2 %) NS
ARBs 13 (13.5 %) 8 (15.7 %) 5 (11.1 %) NS
Calcium antagonists 28 (29.2 %) 18 (35.3 %) 10 (22.2 %) NS
Beta-blockers 50 (52.1 %) 24 (47.1 %) 26 (57.8 %) NS
Nitrates 18 (18.8 %) 7 (13.7 %) 11 (24.4 %) NS
Statins 67 (69.8 %) 36 (70.6 %) 31 (68.9 %) NS
Fibrates 7 (7.3 %) 3 (5.9 %) 4 (8.9 %) NS
PPIs 13 (13.5 %) 6 (11.8 %) 7 (15.6 %) NS
In brackets, percentages of patients in each group taking the appropriate medication are presented
ACE inhibitors angiotensin converting enzyme inhibitor, ARBs angiotensin II receptor blockers, PPIs proton-pump inhibitors
* v2 test
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higher concentration of serum total cholesterol and LDL
cholesterol in comparison to ASA responders. It is con-
sistent with our previous results and literature data [13, 26,
27]. Karepov et al. [13] observed the association between
the lack of antiaggregation and triglicerydaemia despite
ASA intake. Friend et al. [27] noticed ineffective platelet
response to ASA in 69 % of examined patients with
hyperlipidaemia.
The results of our study did not demonstrate the asso-
ciation between ASA dose (75 or 150 mg) and the AR
phenomenon. The other reports concerning this problem
are conflicting. Some authors found that patients taking
smaller doses of ASA had a greater risk of AR [16, 28, 29].
However, such a relationship was not confirmed by large
randomized trials [30].
Similarly to most researchers we found no association
between platelet function and the gender of patients [8, 11].
We also did not observe an association between the age and
AR what is consistent with many reports [8, 11]. Only a
few authors described that the elderly required the
administration of higher doses of ASA to achieve antiag-
gregative effect [9, 31, 32].
Besides, we did not find the association between AR and
increased BMI, similarly to Zytkiewicz et al. [11]. Some
researchers observed higher percentage of AR in obese
patients [13, 33].
We did not observe the association between platelet
reactivity and cardiovascular risk factors except for current
smoking. In the literature there are some reports about
increased AR in people taking ASA and smoking [34–36].
The concentration of 8-izo-PGF2a, the prostaglandin syn-
thesized from arachidonic acid in non-enzymatic process
catalyzed by free radicals, is elevated in smokers. This
substance increases the platelet response to agonists used in
the laboratory tests [37, 38].
The association between AR and the duration of ASA
intake was also reported in the literature. The majority of
researchers noted a higher percentage of ASA non-
responders among patients taking this medication for a
long time, but we did not observe such situation [10, 39]. In
our study mean time of treatment with ASA was signifi-
cantly longer in ASA responders than in ASA non-
responders. It could be associated with significantly
increased concentrations of total and LDL cholesterol, and
higher smoking prevalence in ASA non-responders in
comparison to ASA responders.
Similarly to other authors, we found association between
parameters of CBC and AR [40–42]. ASA non-responders
had higher values of HCT, WBC and PLT in comparison
with ASA responders.
We did not observe a statistically significant association
between AR and other medication taken by examined
patients. In the available literature there are reports that
resistance to antiplatelet medicine is increased in people
treated with NSAIDs (non steroidal anti-inflammatory
drugs), CCB (calcium channel blockers), SSRI (selective
serotonin reuptake inhibitors), ACE inhibitors, beta-
blockers, and PPI (proton pump inhibitors) [9, 43–47]. On
the other hand, it is described that the probability of the
occurrence of ASA resistance was decreased in people
treated with statins, which might be related to the reduction
in the cholesterol level [48]. There are no reports regarding
interactions between ASA and fibrates, nitrates and
angiotensin II receptor blockers.
Conclusions
Results of our study did not confirm the association
between poor glycaemic control in the diabetic patients and
the phenomenon of AR. Lipid disorders are associated with
AR. Diabetic patients who take ASA and smoke are at
greater risk of AR.
Limitation of the study
As the literature data indicate, patient non-compliance is an
important factor which limits ASA effect [49]. In the
examined group of diabetic patients, the regularity of ASA
intake was determined based on the carefully obtained
medical history. Besides, the intake of ASA was personally
controlled by one of the authors on the day (24 h) before
the study.
AR was determined by only one laboratory method, the
whole blood impedance aggregometry using a new-gener-
ation multiple platelet function analyzer. In comparison to
traditional optic aggregometry by Born, this method is
much quicker, less laborious and does not require a special
preparation of the blood sample, hence decreasing the risk
of the laboratory error. The aggregation was measured by
only one agonist, arachidonic acid, as it is suggested for
AR detection.
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